Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
TODAY, JANUARY 25, 2023
AUPH
15:25
Options
Aurinia Pharmaceuticals call volume above normal and directionally bullish
Bullish option flow detected in Aurinia Pharmaceuticals with 5,838 calls trading, 1.1x expected, and implied vol increasing over 1 point to 120.20%. Feb-23 10 calls and Apr-23 12 calls are the most active options, with total volume in those strikes near 1,700 contracts. The Put/Call Ratio is 0.26. Earnings are expected on February 28th.
$AUPH
TheFly.
1, 04, 2023
AUPH, BMY
09:53
Aurinia worth 'keeping closer eye on' after settlement, Dealreporter says
After Aurinia Pharmaceuticals (AUPH) announced a patent settlement with India's Sun Pharmaceuticals regarding lead asset Lupkynis, Dealreporter said in a flash note to its subscribers that it will "be keeping a closer eye" on Aurinia for signs of momentum toward a sale with this patent overhang lifted. The M&A focused publication noted, according to contacts, that Bloomberg reported in late 2021 that Aurinia had received a takeover approach from Bristol-Myers (BMY), but a sale never materialized.
AUPH BMY
BullishBearish
TheFly.com
Portfolio Alerts
Click the Portfolio Name or Symbol to see the research on thefly.com
Main Portfolio matches: PDSB.
TODAY, JUNE 09, 2021
PDSB
07:05
Recommendations
PDS Biotechnology price target raised to $18 from $6.50 at Alliance Global Partners
Alliance Global Partners analyst James Molloy raised the firm's price target on PDS Biotechnology to $18 from $6.50 and keeps a Buy rating on the shares after the company reported additional data from its ongoing PDS0101 Phase 2 triple combination trial in HPV-related cancers at ASCO. He has lowered his discount rate on expected future royalty payments and is now including a separate valuation for PDSB0101 given the recent promising HPV triple combination data and "promising results" from PDS' proprietary Versamune platform, Molloy tells investors.
TheFly.com
AUPH
Portfolio Alerts
Click the Portfolio Name or Symbol to see the research on thefly.com
Main Portfolio matches: AUPH.
TODAY, MAY 24, 2021
AUPH, LLY
12:26
Recommendations
Aurinia reported positive data as competitors 'stumble,' says H.C. Wainwright
H.C. Wainwright analyst Ed Arce noted that Aurinia Pharmaceuticals (AUPH) announced that a "supportive interim analysis" of its AURORA 2 continuation study will be presented at the upcoming European Alliance of Associations for Rheumatology, or EULAR, Congress being held June 2-5. The new data will represent the longest-available outcomes data for LUPKYNIS to date for the treatment of lupus nephritis, or LN, said Arce. Meanwhile, competitor Boehringer Ingelheim announced in a poster presentation at EULAR that its anti-CD40 mAb, BI655064, failed to meet its primary endpoint of complete renal response and Eli Lilly (LLY) disclosed in a recent quarterly filing that TULIP-LN1, its Phase 2 study of anifrolumab, also failed to meet its primary endpoint, according to Arce. The analyst, who maintains his 100% odds of approval view for LUPKYNIS in the U.S., keeps a Buy rating and $35 price target on Aurinia shares.
AUPH LLY
TheFly.com
Portfolio Alerts
Click the Portfolio Name or Symbol to see the research on thefly.com
Main Portfolio matches: AUPH.
TODAY, MAY 20, 2021
AUPH
16:08
Hot Stocks
Aurinia to present 'supportive' AURORA 2 study interim analysis
Aurinia Pharmaceuticals announced that a supportive interim analysis of its AURORA 2 continuation study will be presented at the upcoming European Alliance of Associations for Rheumatology 2021 Congress June 2-5, 2021. Subjects who completed one year of treatment in Aurinia's Phase 3 AURORA study were eligible to enroll in the two-year, blinded, controlled continuation study. The interim analysis to be presented at EULAR evaluated subjects with up to two years of total treatment: one year from AURORA 1 and up to one year in AURORA 2. Previously reported results from AURORA 1 and the Phase 2 AURA-LV study showed that compared with mycophenolate mofetil and low-dose steroids alone, the addition of voclosporin significantly increased the renal response rate and reduced proteinuria, as measured by urine protein creatinine ratio, in subjects with lupus nephritis at approximately one year of treatment. The interim analysis of AURORA 2 showed that subjects in the LUPKYNIS treatment arm sustained meaningful reductions in proteinuria, with no change in mean estimated glomerular filtration rate at 104 weeks of treatment. "Following the enhanced renal response rates achieved in AURORA 1, these additional data show that LUPKYNIS also provides the ability to sustain positive outcomes over time," said Amit Saxena, M.D., Assistant Professor at the Department of Medicine at NYU Langone Medical Center. "The strong and growing pool of data available on LUPKYNIS clearly demonstrates the clinical value and safety of this therapy for a patient population that has historically been challenged with a lack of effective treatment options."
$AUPH AFTER HOURS Quotes LIVE
Data last updated May 12, 2021 05:28 PM ET.
Consolidated Last Sale $11.8 +0.51 (+4.52%)
After-Hours Volume 216,592
After-Hours High $12.02 (04:42:02 PM)
After-Hours Low $11.29 (05:14:21 PM)
AUPH
Something's up?
Buyout?
Rumors everywhere
https://finance.yahoo.com/quote/AUPH210521C00012000?p=AUPH210521C00012000
AUPH Sales Projections
$AUPH Because of the pandemic, Alethia Young (Cantor) currently models $68M and $255M in sales for 2021 and 2022 versus $138M and $572M at one point last year. She sees upside over 2021 if Aurinia can beat her estimates and consensus estimates. pic.twitter.com/mXFeAJJBv6
— Michel Nantel (@MichelNantel) February 14, 2021
$ITRM 13g/a by RA capital 10.6% added 3.7 mill shares.
12 million shares traded already AH
$AUPH "The approved label supports the efficacy and safety of LUPKYNIS as well as Aurinia’s proprietary and patented eGFR pharmacodynamic dosing protocol." 2037 IP protection!!
Halted - news pending
ITRM Denner will do it again!!
My Fl pharmacy discontinued all Vascepa sales last week, now only generic.
AUPH Forget all the noise, just concentrate on this:
Cowen calls Aurinia a best idea for 2021 into FDA action date Aurinia Pharmaceuticals is positioned for a "meaningful inflection" into the January 22 FDA action date for voclosporin in lupus nephritis, Cowen analyst Ken Cacciatore tells investors in a research note. Citing Voclosporin's efficacy and safety, combined with clinician enthusiasm and an unmet clinical need, the analyst has "strong conviction" that voclosporin should be "rapidly incorporated" into the standard of care and has $1B-plus sales potential. He calls Aurinia a best for 2021 and recommends adding to positions at current levels. Cacciatore keeps an Outperform rating on the shares with a $30 price target.
ITRM = Well, if it doesn't work at least they have a patent
Interum Therapeutics announces filing of U.S. patent application
Iterum Therapeutics announced the filing of a U.S. national phase patent application directed to the composition of the bilayer tablet of sulopenem etzadroxil and probenecid and its related uses with the U.S. Patent and Trademark Office. The sulopenem bilayer tablet contains sulopenem etzadroxil, a prodrug of sulopenem that enables oral bioavailability, and probenecid, a renal tubular transport blocking agent, which together enhance the exposure of sulopenem to the bacterial pathogen responsible for the infection. These claims encompass the oral formulation used in the Phase 3 registration studies to support the safety and efficacy of sulopenem etzadroxil and probenecid. An extension of the life of the patent estate would enable pursuit of claims related to our previously granted QIDP indications such as pneumonia.
my most recent positions RGLS-ITRM-LPTX
Long term holdings
AUPH
ARWR
AFMD
CRMD
TRIL --Since May
AKTX (will exit soon)
AUPH is my #1 holding since $5.00
yes, AUPH is my #1 holding, good luck!
ITRM is my second largest position,the fact that Denner is involved got me started on my DD.
A reason this company has huge potential is its work in the antibacterial space. The FDA has made the antibacterial fight a number one priority as many people have become resistant to existing antibiotics, new drugs need to be developed as this is an enormous health care problem, globally.
Creating a great buying opportunity
Looks like Fosco1 was 100% right
TheFly.com ATNM $25 TARGET
TODAY, NOVEMBER 05, 2020
ATNM
08:55
Rec-Initiate
Actinium Pharmaceuticals initiated with a Buy at Alliance Global Partners
Alliance Global Partners analyst Matt Cross initiated coverage of Actinium Pharmaceuticals with a Buy rating and $25 price target.
Related articles
YESTERDAY, NOVEMBER 04, 2020
ATNM
12:23
Hot Stocks
Actinium reports 100% remission rate in third dose cohort of Phase 1 trial
Actinium Pharmaceuticals announced that 100% of evaluable patients in the third and planned final dose cohort of the Actimab-A CLAG-M Phase 1 trial being conducted at the Medical College of Wisconsin achieved remission. Across all three cohorts, 67% or 10/15 patients treated with 0.25, 0.50 and 0.75 uCi/kg of Actimab-A and the standard regimen of CLAG-M achieved a Complete Remission or Complete Remission with inadequate hematopoietic recovery. Further, 83% of patients who received 3 or fewer prior lines of treatment achieved CR or CRi. Notably, 70% of CR/CRi patients were MRD negative indicating a deep remission with no detectable disease. These results which include subtherapeutic doses of Actimab-A in the first two dose cohorts and represent a marked improvement over CLAG-M treatment alone implying potential mechanistic synergy. This novel Phase 1 combination trial is for patients with relapsed or refractory acute myeloid leukemia age 18 and above deemed medically fit for cytotoxic chemotherapy. This data has been accepted for oral presentation at the 2020 American Society of Hematology annual meeting that is being he
KZR still at it, LE & LN
KZR Alert in News Feed
TheFly.com
TODAY, SEPTEMBER 17, 2020
KZR
16:02
Hot Stocks
Kezar Life highlights data from MISSION study during PANLAR 2020
Kezar Life Sciences highlighted data from the Phase 1b portion of the MISSION study demonstrating safety, tolerability and early efficacy signals of KZR-616 in patients with systemic lupus erythematosus and lupus nephritis at the Pan-American Congress of Rheumatology. The data were presented in a poster titled "Treatment of Systemic Lupus Erythematosus with the Immunoproteasome Inhibitor KZR-616: Results from the First 5 Cohorts of the MISSION Study, an Open-label Phase 1b Dose-Escalation Study" by study investigator Richard Furie, M.D., Chief, Division of Rheumatology, Northwell Health in New York. The poster can be found on Kezar's corporate website under the "Science" section. "Lupus and lupus nephritis are life-threatening diseases that disproportionately impact young Latina women in the prime of their life, and there is an urgent need for new treatment options that can target the full spectrum of their disease and don't cause debilitating side effects that add to the disease burden," said Dr. Furie. "These encouraging early positive data suggest that the novel mechanism of KZR-616 has the potential to address the underlying drivers of inflammation, resulting in improvements across organ systems in this disease." MISSION is a Phase 1b/2 study of KZR-616 in SLE patients with and without nephritis. The Phase 1b portion has completed enrollment in the final cohort, which is evaluating a 75 mg dose of KZR-616. The Phase 2 portion exclusively in LN is actively enrolling.
Related articles
FRIDAY, SEPTEMBER
AMRN should have stuck with original lawyers. Too much for Singer to learn in such a short time. It showed
Thanks very much
Thanks Jess
Does anyone know how does KZR's "LN, experienced a greater than 50% reduction in proteinuria" compare to AUPH's Voclosporin?
KZR results-- Will this be a problem for AUPH
The Fly
4:06 PM (49 minutes ago)
to me
KZR Alert in News Feed
See the research on theflyonthewall.com
News Breaks
June 3, 2020
16:06 EDT KZR
Kezar Life Sciences announces updated results from portion of MISSION trial
Kezar Life Sciences announced updated results from the Phase 1b portion of MISSION, which is evaluating the safety and tolerability of KZR-616 in patients with systemic lupus erythematosus, or SLE, with and without nephritis. Overall, improvements were seen across seven measures of disease activity, and two of two patients with lupus nephritis, or LN, experienced a greater than 50% reduction in proteinuria, a biomarker of disease severity. A "positive" safety and tolerability profile was observed with step-up dosing of KZR-616. The Phase 1b dataset builds on the safety and tolerability testing performed in 100 healthy subjects from two Phase 1a studies. As of the May 4 data cutoff, the Ph1b portion of MISSION enrolled 39 SLE patients across five dose cohorts evaluating 45 mg and step-up dosing to 60 mg weekly for 13 weeks. Patients are followed to week 25 and kept on stable background treatment. Below are the results for step-up dosing Cohorts 2a, 2b, and 2c, which enrolled 26 patients. At this time point, a total of 16 patients from these cohorts completed 13 weeks of treatment and are included in the exploratory efficacy measures reported below. Two SLE patients with biopsy-proven lupus nephritis were included in the Phase 1b portion. Both patients showed a greater than 50% reduction in proteinuria as measured by urine protein to creatine ratio, as well as reductions in SLEDAI and reductions in anti-dsDNA antibody levels. Among patients completing treatment in Cohorts 2a and 2b, all seven measures of disease activity improved in the majority of patients from Baseline to Week 13. Improvement in disease activity persisted following t he end-of-treatment. Step-up dosing of KZR-616 improved overall tolerability. Most treatment emergent adverse events, or TEAEs, occurred early and diminished with later doses. To date, no patients have discontinued treatment in Cohorts 2b and 2c, which utilize a lyophilized formulation of KZR-616. The most common treatment emergent adverse events were transient injection site reactions.
Aurinia Pharmaceuticals initiated with an Outperform at Cowen
From the FLY
Aldeyra Therapeutics
Does anyone know if their Dry Eye drug in phase 3 is a threat.
Thanks in advance
Calquence-shows-early-promise-for-covid-19-
https://www.forbes.com/sites/nathanvardi/2020/04/13/exclusive-astrazenecas-calquence-shows-early-promise-for-covid-19-patients/#a1bd2ad4677c
Now you know why Kennedy sold every share he got, for years. Sad.
AUPH
yes, you can convert as retired
and what about settling?
AMRN can afford to give generics a nice royalty on sales to go away for a few years, and then allow them to enter early.
GIVE THEN ROYALTY ON SALES TO GO AWAY